Monte Rosa Therapeutics, Inc. GLUE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $129.88M-42.1% | $224.25M+75.1% | $128.1M+133% | $54.91M-84.1% | ||
| $4.95M+1.9% | $4.86M— | $0-100% | $960K— | ||
| $21.37M-14.3% | $24.94M+46.6% | $17.01M+12.5% | $15.12M+73.9% | ||
| $393.19M+4.2% | $377.44M+59.8% | $236.21M-14.4% | $275.89M-20.9% | ||
| $25.99M-11.9% | $29.48M-12.8% | $33.8M+24.8% | $27.08M+120% | ||
| $24.39M-9.1% | $26.83M-6.9% | $28.81M-17.3% | $34.83M— | ||
| $148K+28.7% | $115K-67.3% | $352K+26.6% | $278K— | ||
| $448.66M+2.3% | $438.73M+44.4% | $303.76M-11.3% | $342.39M-6.5% | ||
| $3.55M-79.4% | $17.22M+54.4% | $11.15M+41.8% | $7.86M+19.9% | ||
| $111.33M+589% | $16.15M-50.0% | $32.32M— | $0— | ||
| $4.4M+18.4% | $3.71M+17.5% | $3.16M+1.1% | $3.13M— | ||
| $64.21M-59.1% | $156.95M+237% | $46.59M+82.2% | $25.57M+53.7% | ||
| $34.79M-10.8% | $39M-9.0% | $42.88M-2.3% | $43.87M— | ||
| $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | ||
| $215.6M-0.1% | $215.8M+73.3% | $124.51M+75.4% | $70.98M+277% | ||
| $0— | $0— | $0— | $0— | ||
| $7K+16.7% | $6K+20.0% | $5K0.0% | $5K0.0% | ||
| $714.09M+7.4% | $664.87M+21.4% | $547.86M+8.8% | $503.7M+6.8% | ||
| -$477.21M-8.8% | -$438.59M-19.9% | -$365.89M-58.7% | -$230.54M-88.9% | ||
| -$3.83M-14.0% | -$3.36M-23.2% | -$2.72M-55.5% | -$1.75M+13.3% | ||
| $233.06M+4.5% | $222.94M+24.4% | $179.25M-34.0% | $271.41M-21.9% | ||
| $448.66M+2.3% | $438.73M+44.4% | $303.76M-11.3% | $342.39M-6.5% | ||
| $7M— | $0— | —— | —— | ||
| $4.6M+2,559% | $173K-65.7% | $505K-93.4% | $7.66M— | ||
| $148K+28.7% | $115K-67.3% | $352K+26.6% | $278K— | ||
| $24.39M-9.1% | $26.83M-6.9% | $28.81M-17.3% | $34.83M— | ||
| $24.39M-9.1% | $26.83M-6.9% | $28.81M-17.3% | $34.83M— | ||
| $148K+28.7% | $115K-67.3% | $352K+26.6% | $278K— | ||
| $24.39M-9.1% | $26.83M-6.9% | $28.81M-17.3% | $34.83M— | ||
| $148K+28.7% | $115K-67.3% | $352K+26.6% | $278K— | ||
| $26.69M+42.1% | $18.79M+28.7% | $14.6M+0.1% | $14.58M+44.6% | ||
| $29.57M-74.8% | $117.23M+563% | $17.68M— | $0— | ||
| $5.27M+42.2% | $3.7M+36.5% | $2.71M+77.0% | $1.53M-29.5% | ||
| $39.19M-8.3% | $42.72M-7.2% | $46.04M-2.0% | $47M+535% | ||
| $714.09M+7.4% | $664.87M+21.4% | $547.86M+8.8% | $503.7M+6.8% | ||
| $7K+16.7% | $6K+20.0% | $5K0.0% | $5K0.0% | ||
| $0— | $0— | $0— | $0— | ||
| $5.27M+42.2% | $3.7M+36.5% | $2.71M+77.0% | $1.53M-29.5% | ||
| $4.6M+2,559% | $173K-65.7% | $505K-93.4% | $7.66M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Monte Rosa Therapeutics, Inc.'s total assets?
- Monte Rosa Therapeutics, Inc. (GLUE) holds $736.4M in total assets, up 87.3% year over year.
- How much debt does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. carries $39.1M in total debt against $521.9M of shareholders' equity, a debt-to-equity ratio of 0.07.
- How much cash does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. holds $159.9M in cash and equivalents.
- Can Monte Rosa Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 9.54 — current assets exceed current liabilities.
- Where does Monte Rosa Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
